Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Marc Espié"'
Autor:
Michel Marty, Marc Espié, Barbara Pistilli, Sylvie Giacchetti, Junheng Gao, Enora Laas, Sandrine Tury, F Reyal, Brice Aouchiche, Jean-Yves Pierga, E. Brain, Martin J. Edelman, Bernard Asselain, Gabriel Benchimol, Marick Laé, Xiaofei Wang, Anne-Sophie Hamy
Publikováno v:
Journal of Clinical Oncology. 37:624-635
PURPOSE The overexpression of cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs in breast cancer, but whether it affects response to anticox drugs remains unclear. We investigated the relationships be
Autor:
Stéphanie Bécourt, Sylvie Giacchetti, Luis Augusto Teixeira, Odile Cohen-Haguenauer, Caroline Cuvier, E. Bourstyn, LaurenceDoidy Cahen-Doidy, Florence Ledoux, Marc Espié, Olivia Nguyen
Publikováno v:
Journal of Clinical Oncology. 36:e13522-e13522
e13522Background: BRCA-1 and 2 are two major susceptibility genes for BC. We compared CP features and outcome in (i) BRCA (1/2)-mutation carrier’s patients, (ii) patients with a family history sugg...
Autor:
Stina M. Singel, Matthew Wongchenko, Rebecca Dent, Daniel J. Maslyar, Mafalda Oliveira, Amy V. Kapp, Sung-Bae Kim, Sibel Blau, Marc Espié, José Baselga, Cristina Saura, Steven J. Isakoff, Seock-Ah Im, Wai Y. Chan, Antoinette R. Tan
Publikováno v:
Journal of Clinical Oncology. 36:1008-1008
1008Background: In LOTUS (NCT02162719), adding the oral AKT inhibitor IPAT to first-line PAC for mTNBC improved progression-free survival (PFS; primary endpoint) [Kim, Lancet Oncol 2017]. The strat...
Autor:
Ta-Chung Chao, Laslo Roman, Hugues Bourgeois, Yuri Demidchik, Vasili Beliakouski, Christelle Levy, Marc Espié, Javier Cortes, Jean-Marc Ferrero, Corinne Veyret, Jean-Marc Nabholtz, Yauheniya Karchmit, Mario Campone, Xavier Gonzalez, Simon Spazzapan
Publikováno v:
Journal of Clinical Oncology. 33:1031-1031
1031 Background: There is currently no consensus on the efficacy of chemotherapy (CT) beyond 3rd line in MBC and only eribulin (which has been recently approved) has shown to improve survival. No p...
Autor:
Marc Espié, Jacqueline Lehmann Che, Luis Augusto Teixeira, Florence Coussy, Anne de Roquancourt, Philippe Bertheau, Caroline Cuvier, Marjorie Lalloum, Patricia de Cremoux, Matthieu Resche Rigon, Alice Sanna, Brigitte Poirot, Fatiha Bouhidel, Sylvie Giacchetti
Publikováno v:
Journal of Clinical Oncology. 33:e11607-e11607
e11607 Background: Breast cancer (BC) is a heterogeneous disease with different prognostic according to molecular characteristics. About 15% of breast cancers have erbb2 oncogene (HER2+) overexpres...
Autor:
Keyvan Rezai, Eric Leblanc, Jacques Bonneterre, Catherine Lhommé, Paul Cottu, Erard M. Gilles, Anas Gazzah, Alexander Zukiwski, Sylvie Giacchetti, François Lokiec, Véronique Diéras, Marc Espié, Alice Bexon, Joseph Bisaha, Andrea Varga
Publikováno v:
Journal of Clinical Oncology. 32:TPS2643-TPS2643
TPS2643 Background: ONA is a type I PR antagonist, which prevents PR-induced DNA transcription. Presence of transcriptionally activated PR (APR), could indicate potential for ONA anticancer activit...
Autor:
Sandrine Lavau-Denes, Marie Antoinette Sevestre, Joseph Gligorov, Marc Espié, Antoine Elias, Philippe Debourdeau, Sylvie Chevret, Laurent Bastit, Dominique Farge, Pierre-Francois Dupre, Issa Kalidi, Joel LeLong
Publikováno v:
Journal of Clinical Oncology. 32:e20616-e20616
e20616 Background: With increased use of central venous catheters (CVC) in cancer patients, CVC-Related thrombosis (CRT) reported in about 5% of cases, represents a major problem in oncology practi...
Autor:
Robert Paridaens, D. Trukhin, Balaji Keshavrao Shewalkar, Henri Roché, Auro Del Giglio, Anantbhushan Ranade, Marc Espié, Henry L. Gomez, Roberto Hegg, Guillermo Lerzo, Denis Talbot, Corinne Veyret, Elżbieta Starosławska, D. Lokanatha, Armando Santoro, Dina Sakaeva, Antonio Llombart
Publikováno v:
Journal of Clinical Oncology. 32:1011-1011
1011 Background: Paclitaxel (PTX), plus gemcitabine (GEM) showed survival advantage over paclitaxel in advanced breast cancer (ABC) patients who relapsed after adjuvant anthracycline. This was asso...
Autor:
Miguel Martín, Marc Espié, Sonia Extremera, Pilar Lardelli, Eva M. Fernández-García, Philippe Aftimos, Ahmad Awada, Mafalda Oliveira, Carmen Kahatt, Suzette Delaloge, Javier Cortes
Publikováno v:
Journal of Clinical Oncology. 30:TPS652-TPS652
TPS652 Background: Hormone receptor-positive, HER2-negative breast cancer (BC) is currently associated with 3-4 years overall survival in the metastatic setting and, after ≥2 relapses, therapeutic approaches are reduced. XPG expression is frequentl
Autor:
A. Tres, R. C. Coombes, Pierre Hupperets, Frans L. G. Erdkamp, Judith M Bliss, J. Wals, J. A. Reise, Marc Espié, Derek Cooper, Robert E. Coleman
Publikováno v:
Journal of Clinical Oncology. 28:536-536
536 Background: This group previously showed that fractionated epirubicin (EPI) alone is an active, well tolerated adjuvant regimen in postmenopausal women (Wils, JCO, 1999). DEVA evaluated the efficacy and toxicity of incorporating docetaxel (DOC) t